Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical …

D Follmann, HE Janes, OD Buhule, H Zhou… - Annals of Internal …, 2022 - acpjournals.org
Background: Immunoassays for determining past SARS-CoV-2 infection have not been
systematically evaluated in vaccinated persons in comparison with unvaccinated persons …

Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies

HT Zedan, HM Yassine, DW Al-Sadeq, N Liu… - Scientific reports, 2022 - nature.com
Rapid and accurate measurement of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV2)-specific neutralizing antibodies (nAbs) is paramount for monitoring immunity …

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals

DW Al-Sadeq, FM Shurrab, A Ismail… - Journal of Travel …, 2021 - academic.oup.com
Abstract Background Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273,
obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is …

A highly sensitive and specific SARS-CoV-2 spike-and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies

A Solastie, C Virta, A Haveri, N Ekström… - Microbiology …, 2021 - Am Soc Microbiol
Validation and standardization of accurate serological assays are crucial for the surveillance
of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. We …

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial

D Follmann, HE Janes, OD Buhule, H Zhou, B Girard… - medRxiv, 2022 - medrxiv.org
Importance The performance of immunoassays for determining past SARS-CoV-2 infection,
which were developed in unvaccinated individuals, has not been assessed in vaccinated …

Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection

LJ Abu-Raddad, H Chemaitelly, HH Ayoub… - Medrxiv, 2021 - medrxiv.org
Abstract Effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Here, we investigated whether persons vaccinated after a prior infection have …

[HTML][HTML] Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2-IgG antibodies using advanced detection assays

FM Shurrab, DW Al-Sadeq, FH Amanullah, ES Al-Absi… - Intervirology, 2022 - karger.com
Several studies have reported serological cross-reactivity of the immune responses between
SARS-CoV-2 and DENV. Most of the available studies are based on the point-of-care rapid …

Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections

LJ Abu-Raddad, H Chemaitelly, HH Ayoub, P Tang… - medRxiv, 2021 - medrxiv.org
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior
infection have been observed globally, but the transmission potential of these infections is …

Clinical evaluation of SARS-CoV-2 antigen-based rapid diagnostic test kit for detection of COVID-19 cases in Bangladesh

MM Rahman, AF Hoque, Y Karim, Z Kawser, AB Siddik… - Heliyon, 2021 - cell.com
The rapid and early detection of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infections is key to control the current Coronavirus disease 2019 (COVID-19) …

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A …

FM Shurrab, DW Al-Sadeq, H Abou-Saleh, N Al-Dewik… - Vaccines, 2022 - mdpi.com
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-
1273, offer great promise for reducing the spread of the COVID-19 by generating protective …